New drug GenSci098 enters first human trial for thyroid eye disease
NCT ID NCT06569758
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 31 times
Summary
This early-stage trial is testing a new drug called GenSci098 in 76 adults with active thyroid eye disease (TED). The main goal is to check the drug's safety and how the body processes it at different doses. Participants will receive either the drug or a placebo as a shot under the skin, and researchers will monitor for side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOLERABILITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Ninth People's hospital, Shanghai Jiaotong University School of Medication
RECRUITINGShanghai, Shanghai Municipality, 200011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GenSci098
What this could lead to
If successful, this could lead to a new treatment option for thyroid eye disease, potentially reducing symptoms like eye bulging and discomfort.
What could go wrong
This is a very early Phase 1 trial focused on safety, not yet on effectiveness. The drug may not work as hoped, and side effects are unknown at this stage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.